CCHFV vaccine development, current challenges, limitations, and future directions

Büşra Ahata; Büşra Ahata; Günseli Bayram Akçapınar

doi:10.3389/fimmu.2023.1238882

Frontiers in Immunology (Sep 2023)

CCHFV vaccine development, current challenges, limitations, and future directions

Büşra Ahata,
Büşra Ahata,
Günseli Bayram Akçapınar

Affiliations

Büşra Ahata: Department of Medical Biotechnology, Institute of Health Sciences, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Türkiye
Büşra Ahata: Health Institutes of Turkey, Istanbul, Türkiye
Günseli Bayram Akçapınar: Department of Medical Biotechnology, Institute of Health Sciences, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Türkiye

DOI: https://doi.org/10.3389/fimmu.2023.1238882
Journal volume & issue: Vol. 14

Abstract

Read online

Crimean-Congo hemorrhagic fever (CCHF) is the most prevalent tick-borne viral disease affecting humans. The disease is life-threatening in many regions of the developing world, including Africa, Asia, the Middle East, and Southern Europe. In line with the rapidly increasing disease prevalence, various vaccine strategies are under development. Despite a large number of potential vaccine candidates, there are no approved vaccines as of yet. This paper presents a detailed comparative analysis of current efforts to develop vaccines against CCHFV, limitations associated with current efforts, and future research directions.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords